Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$20.78 USD
-0.37 (-1.75%)
Updated Jul 19, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Nurix Therapeutics, Inc falls in the month of November.
All items in Millions except Per Share data.
11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 288 | 309 | 296 | 281 | 38 |
Receivables | 0 | 0 | 6 | 4 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 9 | 9 | 13 | 2 |
Total Current Assets | 296 | 318 | 311 | 298 | 39 |
Net Property & Equipment | 17 | 17 | 11 | 7 | 4 |
Investments & Advances | 7 | 64 | 137 | 91 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 3 | 0 | 0 |
Total Assets | 356 | 417 | 477 | 396 | 44 |
Liabilities & Shareholders Equity | 11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 5 | 7 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 25 | 22 | 15 | 8 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 48 | 38 | 41 | 33 | 10 |
Total Current Liabilities | 87 | 71 | 66 | 45 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 45 | 36 | 59 | 61 | 36 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 48 |
Total Liabilities | 155 | 113 | 134 | 106 | 102 |
Shareholders Equity | 11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 746 | 709 | 564 | 394 | 3 |
Retained Earnings | -545 | -401 | -221 | -104 | -60 |
Other Equity | -1 | -4 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 200 | 304 | 342 | 290 | -58 |
Total Liabilities & Shareholder's Equity | 356 | 417 | 477 | 396 | 44 |
Total Common Equity | 200 | 304 | 342 | 290 | -58 |
Shares Outstanding | 48.50 | 47.10 | 44.60 | 38.80 | NA |
Book Value Per Share | 4.13 | 6.45 | 7.67 | 7.48 | 0.00 |
Fiscal Year End for Nurix Therapeutics, Inc falls in the month of November.
All items in Millions except Per Share data.
5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 443 | 244 | 288 | 259 | 281 |
Receivables | 0 | 0 | 0 | 2 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 7 | 8 | 7 | 9 |
Total Current Assets | 450 | 251 | 296 | 268 | 290 |
Net Property & Equipment | 19 | 18 | 17 | 17 | 19 |
Investments & Advances | 9 | 10 | 7 | 10 | 27 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 4 | 5 | 5 | 5 |
Total Assets | 511 | 313 | 356 | 308 | 351 |
Liabilities & Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 6 | 6 | 2 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 23 | 28 | 25 | 22 | 18 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 47 | 46 | 48 | 32 | 44 |
Total Current Liabilities | 81 | 88 | 87 | 61 | 72 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 39 | 34 | 45 | 10 | 15 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 140 | 144 | 155 | 74 | 91 |
Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,002 | 756 | 746 | 738 | 728 |
Retained Earnings | -631 | -587 | -545 | -503 | -466 |
Other Equity | 0 | 0 | -1 | -1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 371 | 169 | 200 | 234 | 260 |
Total Liabilities & Shareholder's Equity | 511 | 313 | 356 | 308 | 351 |
Total Common Equity | 371 | 169 | 200 | 234 | 260 |
Shares Outstanding | 64.30 | 49.10 | 48.50 | 48.20 | 47.40 |
Book Value Per Share | 5.77 | 3.44 | 4.13 | 4.85 | 5.48 |